• Twitter
  • RSS
InterveXion Therapeutics
  • About Us
    • Overview
    • Management Team and Founders
    • Financial Conflict of Interest
  • Research & Development
    • Anti-Methamphetamine Products
    • Intellectual Property
    • Methamphetamine Use Statistics
  • Publications
    • Recent Publications
    • Anti-Methamphetamine Monoclonal Antibody
    • METH Vaccine
    • Anti-Phencyclidine Monoclonal Antibody
    • Review Articles
  • Contact Us
  • News
Select Page

InterveXion’s First IND Application Becomes Active

Apr 12, 2012 | Anti-METH ch-mAb7F9, Uncategorized

An IND for InterveXion’s chimeric anti-METH monoclonal antibody, ch-mAb7F9, was submitted to FDA in March and became active in early April. Plans for the Phase 1a clinical study in healthy volunteers are being finalized and we expect to begin screening potential...

Recent Posts

  • InterveXion to Present IXT-m200 Program and Phase 2 STAMPOUT Study Design at Upcoming College on Problems in Drug Dependence Meeting
  • InterveXion Enrolls First Patient in Phase 2 Study of the Effect of IXT-m200 on Methamphetamine PK and PD
  • InterveXion Licenses Asian Rights to Novel Anti-Methamphetamine Antibody to Ascent Therapeutics
  • InterveXion Awarded $8M to Fund Phase 2 Clinical Study of Anti-Methamphetamine Medication
  • STAMPOUT study to be conducted in METH users when funded

Recent Comments

    Archives

    • May 2018
    • January 2018
    • October 2017
    • June 2017
    • January 2016
    • January 2015
    • November 2014
    • February 2014
    • August 2013
    • July 2013
    • December 2012
    • November 2012
    • May 2012
    • April 2012
    • July 2011
    • April 2011
    • October 2009
    • September 2009
    • March 2005
    • January 2005

    Categories

    • Anti-METH ch-mAb7F9
    • Anti-METH Vaccine
    • Anti-PCP ch-mAb6B5
    • General News
    • Grants
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Twitter
    • RSS
    © 2017 Intervexion